A human IgG1 broadly neutralizing monoclonal antibody engineered with an LS Fc mutation for extended half-life; recognizes the HIV-1 Env gp120 V3 glycan (N332) patch to neutralize virions and can mediate Fc-dependent effector functions.
Human IgG1 broadly neutralizing monoclonal antibody with an LS Fc mutation for extended half-life that binds the HIV-1 Env gp120 V3 glycan (N332) patch to block viral attachment/entry and neutralize circulating virions; its Fc domain can engage Fc receptors to mediate ADCC/ADCP against Env-expressing infected cells.
YES
INDIRECT
The IgG1 antibody binds Env on infected cells and engages Fcγ receptor–bearing effector cells to mediate ADCC/ADCP (and potentially complement activation), resulting in immune-mediated killing/clearance of the target cells.
A human IgG1 broadly neutralizing monoclonal antibody engineered with an LS Fc mutation for extended half-life; recognizes the HIV-1 Env gp120 V3 glycan (N332) patch to neutralize virions and can mediate Fc-dependent effector functions.
Human IgG1 broadly neutralizing monoclonal antibody with an LS Fc mutation for extended half-life that binds the HIV-1 Env gp120 V3 glycan (N332) patch to block viral attachment/entry and neutralize circulating virions; its Fc domain can engage Fc receptors to mediate ADCC/ADCP against Env-expressing infected cells.
NO
INDIRECT
PGT121.414.LS engages FcRn via its LS Fc mutation only for IgG recycling and extended half-life; it does not kill FcRn-expressing cells. Cytotoxicity, when present, is via Fcγ receptor–mediated ADCC/ADCP against HIV Env–expressing infected cells, not via FcRn.
A human IgG1 broadly neutralizing monoclonal antibody engineered with an LS Fc mutation for extended half-life; recognizes the HIV-1 Env gp120 V3 glycan (N332) patch to neutralize virions and can mediate Fc-dependent effector functions.
Human IgG1 broadly neutralizing monoclonal antibody with an LS Fc mutation for extended half-life that binds the HIV-1 Env gp120 V3 glycan (N332) patch to block viral attachment/entry and neutralize circulating virions; its Fc domain can engage Fc receptors to mediate ADCC/ADCP against Env-expressing infected cells.
NO
INDIRECT
The antibody’s Fc binds CD16a on NK/monocytes to trigger ADCC/ADCP against HIV Env–expressing infected cells; CD16a+ cells are effector cells and are not killed by the drug.
A human IgG1 broadly neutralizing monoclonal antibody engineered with an LS Fc mutation for extended half-life; recognizes the HIV-1 Env gp120 V3 glycan (N332) patch to neutralize virions and can mediate Fc-dependent effector functions.
Human IgG1 broadly neutralizing monoclonal antibody with an LS Fc mutation for extended half-life that binds the HIV-1 Env gp120 V3 glycan (N332) patch to block viral attachment/entry and neutralize circulating virions; its Fc domain can engage Fc receptors to mediate ADCC/ADCP against Env-expressing infected cells.
NO
INDIRECT
The antibody binds HIV-1 Env on infected cells; its Fc engages Fc-gamma receptors such as CD32a on effector cells to mediate ADCC/ADCP against Env-expressing targets. CD32a-expressing cells themselves are not targeted or killed.
An anti‑HER2 antibody–drug conjugate consisting of a humanized anti‑HER2 monoclonal antibody linked to the microtubule inhibitor MMAE; kills HER2‑expressing tumor cells with a bystander effect.
Humanized anti-HER2 monoclonal antibody conjugated to the microtubule inhibitor MMAE. Binds HER2 on tumor cells, is internalized, and releases MMAE via a cleavable linker to disrupt microtubules, causing G2/M arrest and apoptosis; cytotoxic payload can diffuse for a bystander effect on neighboring cells with lower HER2 expression.
YES
DIRECT
Anti-HER2 ADC binds HER2, is internalized, and releases MMAE via a cleavable linker; MMAE disrupts microtubules causing G2/M arrest and apoptosis (with possible bystander killing).